← Back to Clinical Trials
Recruiting NCT06832839

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

Trial Parameters

Condition Moyamoya Disease
Sponsor Beijing Tiantan Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 360
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2024-12-16
Completion 2025-12-31
Interventions
Revascularization

Brief Summary

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Eligibility Criteria

Inclusion Criteria: * The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age. Exclusion Criteria: * Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments

Related Trials